Investors are bullish on the stock due to the recent pipeline progress. Last month, the FDA cleared the company's investigational new drug application or 4D-175, an R100 vector-based intravitreal genetic medicine, for the treatment of patients with geographic atrophy. Earlier, the company presented positive data on its lead candidate, 4D-150, in wet age-related macular degeneration. While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical resear ...